Fresenius Nephrocare Romania S.R.L.
- Address
- lock Available on a paid plan
Cardiovascular Diseases Research
At Fresenius Nephrocare Romania S.R.L. in Iasi, the clinical trial portfolio focuses on Cardiovascular Diseases in people with advanced kidney disease. The main research themes include atherosclerotic cardiovascular disease in patients with ESKD and strategies to reduce arteriovenous graft thrombosis, reflecting a strong interest in heart and vessel complications linked to dialysis care.
- Studying atherosclerotic cardiovascular disease in end-stage kidney disease to better understand risk and treatment impact
- Evaluating a new therapy aimed at lowering inflammation markers such as hs-CRP in dialysis patients
- Assessing approaches to prevent arteriovenous graft thrombosis and support safer vascular access
These studies are designed to improve treatment effectiveness and patient outcomes in dialysis-related cardiovascular care, with attention to both disease control and the preservation of access for ongoing therapy.
Nephrology-Centered Clinical Research
The Nefrologie department is conducting a small but focused set of trials that connect kidney disease with major cardiovascular complications. Research here is centered on patients receiving maintenance dialysis, with the goal of finding better ways to manage inflammation, reduce vascular events, and improve long-term care in ESKD.
- Testing a potential therapy for adults with ESKD undergoing dialysis to help lower inflammatory burden
- Comparing an investigational treatment with placebo to delay the first arteriovenous graft thrombosis event
Overall, the research activity at this hospital/clinic site is aimed at advancing both diagnostic insight and therapeutic options for patients whose kidney disease is closely tied to cardiovascular risk.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 1 by active trials.
- 1CSL Behring LLC1active
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
No repeated partnerships found.
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 442 other sites in Romania
Therapeutic Area Benchmark — Romania
Select a therapeutic area to compare against other sites in Romania.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Romania
Market Share
Country: Romania
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Fresenius Nephrocare Romania S.R.L.
lock Showing 1 of 2 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| A Phase 2b/3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Combined Dose-Finding and Cardiovascular Outcome Study to Investigate the Efficacy and Safety of CSL300 (Clazakizumab) in Subjects with End Stage Kidney Disease Undergoing Dialysis | CSL Behring LLC | Phase IV | Recruiting | Jul 2023 | — |
IMP list
lock Showing 1 of 2 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Clazakizumab | 1 | Unknown | 2023-07-17 | 2023-07-17 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.